Neurocrine Biosciences, Inc.
Treatment of congenital adrenal hyperplasia

Abstract:

CRF.sub.1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.